CEO Insights Team
According to healthcare estimates, kidney disease is the third biggest killer after cancer and cardiac ailments globally. Nearly 200,000 kidney failures occur in India annually with six out of ten patients suffering from kidney disease (CKD), diabetes and hypertension. The prevalence of end-stage renal disease requiring a transplant in India is estimated to be between 151 and 232 per million of the population. Kidney disease has indeed assumed worrisome proportions in India.
At CORE, we run the rarest of high-end diagnostic markers on renal biopsy samples that help us come up with a definitive diagnosis along with prognostic information for the treating physician
The Brain Behind Development
Owning to its high-end diagnostics capabilities, CORE continuously invests resources and talent n identifying and introducing novel diagnostics, which are critical in combating complicated diseases including chronic kidney disease. The company brings ease to clinicians’ lives through real-time data collection done via easy shipping and doorstep sample collection and uses special collection kits only for better sample stability, quality reporting and faster turnaround time.
On the occasion, Zoya Brar, Founder & MD, CORE Diagnostics asserts “Unsuccessful or inadequate clinical intervention impose heavy financial burden on patients. We are confident that with the newest addition of nephrology diagnostic services, we will improve the healthcare outcomes and quality of lives of the patients we serve”. Adding to that, Dr. Rajan Duggal, Vice President nephroCORE says, “Kidney biopsies are the gold-standard for the diagnosis of medical and transplant kidney disorders. At CORE, we run the rarest of high-end diagnostic markers on renal biopsy samples that help us come up with a definitive diagnosis along with prognostic information for the treating physician”.
The vent also marked attendance of Dr. Vijay Kher (Medanta Hospital) who spoke about ‘Renal Biopsy reporting: Expectations of a Nephrologist’, Dr. Dinesh Khullar (Max Hospital, Saket), Dr. P.P Varma (Venkateshwara Hospital), Dr. Manju Aggarwal (Artemis Hospital) and Dr. Saurabh Pokhariyal (Manipal Hospital) who participated in panel discussion on ‘Interesting Renal Biopsies’ moderated by Dr. Vivekanand Jha, President International Society of Nephrology.
Owning to its high-end diagnostics capabilities, CORE continuously invests resources and talent n identifying and introducing novel diagnostics, which are critical in combating complicated diseases including chronic kidney disease. The company brings ease to clinicians’ lives through real-time data collection done via easy shipping and doorstep sample collection and uses special collection kits only for better sample stability, quality reporting and faster turnaround time.
On the occasion, Zoya Brar, Founder & MD, CORE Diagnostics asserts “Unsuccessful or inadequate clinical intervention impose heavy financial burden on patients. We are confident that with the newest addition of nephrology diagnostic services, we will improve the healthcare outcomes and quality of lives of the patients we serve”. Adding to that, Dr. Rajan Duggal, Vice President nephroCORE says, “Kidney biopsies are the gold-standard for the diagnosis of medical and transplant kidney disorders. At CORE, we run the rarest of high-end diagnostic markers on renal biopsy samples that help us come up with a definitive diagnosis along with prognostic information for the treating physician”.
The vent also marked attendance of Dr. Vijay Kher (Medanta Hospital) who spoke about ‘Renal Biopsy reporting: Expectations of a Nephrologist’, Dr. Dinesh Khullar (Max Hospital, Saket), Dr. P.P Varma (Venkateshwara Hospital), Dr. Manju Aggarwal (Artemis Hospital) and Dr. Saurabh Pokhariyal (Manipal Hospital) who participated in panel discussion on ‘Interesting Renal Biopsies’ moderated by Dr. Vivekanand Jha, President International Society of Nephrology.